Table 3 Demographic, clinical, immunological and histopathological characteristics and outcome of type II RPGN

Age (years)

26.9 (4.5)

37 (3.5)

25 (0.0)

45 (0.0)

50 (4.5)

Gender (%)

 Male

 Female

4 (11.8%)

30 (88.2%)

2 (50%)

2 (50%)

2 (100%)

0 (0.0%)

0 (0.0%)

2 (100%)

6 (100%)

0 (0.0%)

Edema (%)

26 (76.5%)

2 (50%)

2 (100%)

0 (0.0%)

0 (0.0%)

Microscopic hematuria (%)

34 (100%)

0.0 (0.0%)

2 (100%)

2 (100%)

2 (33.3%)

Macroscopic hematuria (%)

0.0 (0.0%)

4 (100%)

0.0 (0.0%)

0.0 (0.0%)

4 (66.7%)

Oliguria (%)

20 (58.8%)

4 (100%)

2 (100%)

0.0 (0.0%)

4 (66.7%)

Fever (%)

16 (47.1%)

0.0 (0.0%)

0.0 (0.0%)

2 (100%)

0.0 (0.0%)

Skin rash (%)

22 (64.7%)

0.0 (0.0%)

0.0 (0.0%)

2 (100%)

6 (100%)

Hemoptysis (%)

8 (23.5%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

Arthritis (%)

26 (76.5%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

4 (66.7%)

Need for HD at presentation (%)

20 (58.8%)

2 (50%)

2 (100%)

2 (100%)

4 (66.7%)

Serum creatinine at presentation (mg/dL)

4.4 (2.1)

4.6 (1.6)

3.5 (0.0)

2.7 (0.0)

5.3 (2.1)

eGFR at presentation (ml/min/1.73²)

19.5 (12.8)

15.5 (8.7)

23 (0.0)

20 (0.0)

16.3 (10.7)

Hb (gm/dL)

8.5 (0.9)

9.2 (0.9)

10 (0.0)

9.6 (0.0)

8.8 (0.2)

Serum albumin (gm/dL)

2.2 (0.5)

2.6 (0.6)

2.1 (0.0)

3.1 (0.0)

2.7 (0.4)

Proteinuria (gm/day)

5.8 (2)

4 (0.6)

8 (0.0)

4.7 (0.0)

4.3 (0.2)

Low C3 (%)

34 (100%)

0.0 (0.0%)

0.0 (0.0%)

2 (100%)

6 (100%)

Low C4 (%)

34 (100%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

+ve ANA (%)

34 (100%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

+ve AntidsDNA (%)

34 (100%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

+ve AntiGBM Ab (%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

+ve P-ANCA (%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

+ve C-ANCA (%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

Number of sclerotic glomeruli

3.9 (2.5)

3 (2.3)

2 (0.0)

2 (0.0)

5.3 (1.4)

Number of crescentic glomeruli

11.9 (2.5)

13.5 (6.3)

10 (0.0)

15 (0.0)

11 (1.5)

Number of fibrous crescents

2.5 (1.5)

2.5 (0.6)

1 (0.0)

3 (0.0)

2.7 (0.5)

Number of cellular crescents

9.3 (2.3)

10.5 (6.3)

9 (0.0)

12 (0.0)

8.3 (1.4)

Glomerular lesions (%)

 Endocapillary proliferation (%)

 Mesangial proliferation (%)

 Neutrophilic infiltration (%)

 Glomerular thrombosis (%)

34 (100%)

16 (47.1%)

22 (64.7%)

0.0 (0.0%)

4 (100%)

4 (100%)

4 (100%)

0.0 (0.0%)

2 (100%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

2 (100%)

2 (100%)

2 (100%)

0.0 (0.0%)

6 (100%)

4 (66.7%)

4 (66.7%)

0.0 (0.0%)

Moderate to severe IFTA (%)

18 (52.9%)

2 (50%)

0.0 (0.0%)

2 (100%)

2 (33.3%)

TLO formation (%)

14 (41.2%)

2 (50%)

0.0 (0.0%)

0.0 (0.0%)

6 (100%)

Vascular lesions

 Fibrinoid necrosis (%)

 Severe arteriosclerosis (%)

11 (32.4%)

18 (52.9%)

0.0 (0.0%)

2 (50%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

4 (66.7%)

6 (100%)

Primary outcomes

 ESRD

22 (64.7%)

2 (50%)

0.0 (0.0%)

2 (100%)

4 (66.7%)

 Death

10 (29.4%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

2 (33.3%)

 Partial remission

8 (23.5%)

0.0 (0.0%)

2 (100%)

0.0 (0.0%)

2 (33.3%)

 Complete remission

4 (11.8%)

2 (50%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

Secondary outcomes

 Infections

16 (47.1%)

0.0 (0.0%)

0.0 (0.0%)

2 (100%)

4 (66.7%)

 Heart failure

12 (35.3%)

2 (50%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

 Respiratory failure

14 (41.2%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

 Diabetes mellitus

8 (23.5%)

0.0 (0.0%)

0.0 (0.0%)

0.0 (0.0%)

2 (33.3%)